NCT00819377View on ClinicalTrials.gov

Milrinone Inhaled in Cardiac Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

January 31, 2012

Study Completion Date

December 31, 2012

Conditions
Valvular StenosisValvular InsufficiencyHypertension, PulmonaryCoronary Artery Disease
Interventions
DRUG

Milrinone

inhaled milrinone 5 mg (as for the injectable solution)

DRUG

Normal saline

5 ml normal saline by inhalation over 15 min

Trial Locations (1)

H1T 1C8

Montreal Heart Institute, Montreal

Sponsors

Collaborators (1)

Organon
All Listed Sponsors
collaborator

Heart and stoke fondation of Quebec

UNKNOWN

collaborator

Organon

INDUSTRY

collaborator

Canadian Anesthesiologists' Society

OTHER

lead

Andre Denault

OTHER